Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade

Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade

Item
http://www.wikidata.org/entity/Q28547529
Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantationThe Daniel K. Inouye College of Pharmacy Scripts: Hepatitis C in 2015: Recent Advancements and Current ChallengesEvaluating a Collaborative Approach to Improve Prior Authorization Efficiency in the Treatment of Hepatitis C VirusLong-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor.Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United StatesHepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents.Engagement in Care of High-Risk Hepatitis C Patients with Interferon-Free Direct-Acting Antiviral Therapies.Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series.Going Viral: Why Eliminating the Burden of Hepatitis C Requires Enhanced Cooperation Between Specialists and Primary Care Providers.The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions.Response to Liu et al.Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era.Obstacles to successful treatment of hepatitis C in uninsured patients from a minority population.Patterns in Liver-Related Health Outcomes with Hepatitis C Virus Treatments and Health Equity Implications for Decision Makers: A Cohort Analysis of Medicaid PatientsDRUG PRICING & CHALLENGES TO HEPATITIS C TREATMENT ACCESS
P2860

Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade

Item
http://www.wikidata.org/entity/Q28547529
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@ast
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@en
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@nl
type
label
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@ast
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@en
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@nl
prefLabel
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@ast
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@en
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@nl
P1433
P1476
P2093
P2860
P304
P31
P3181
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932
P3181
P356
P1433
P1476
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@en
P2093
P2860
P304
P31
P3181
P356
10.1371/JOURNAL.PONE.0135645
P407
P433
P478
P50
P577
P5875
P698
P921
P932